An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Granix

Chemical Nametbo-filgrastim
Dosage FormInjection (subcutaneous; 300 mcg/ 0.5 mL, 480 mcg/ 0.8 mL)
Drug ClassMiscellaneous
SystemBlood
CompanyTeva Pharmaceuticals
Approval Year2012

Indication

  • Indicated for the reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia
Last updated on 4/11/2022

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Neutroval (tbo-filgrastim) Prescribing Information.2012Teva Pharmaceuticals USA, North Wales, PA
Document TitleYearSource
Results of a prospective tandomized, open-label, noninferiority study of tbo-filgrastim (granix) versus filgrastim (neupogen) in combination with plerixafor for autologous stem cell mobilization in patients with multiple myeloma and non-hodgkin lymphoma.2017Biology of Blood and Marrow Transplantation